Conditions that impair one's capacity to remember, retain, or process information are referred to as memory disorders. They may be brought on by infections, brain trauma, stroke, or neurodegenerative illnesses including Parkinson's and Alzheimer's. Mild forgetfulness to severe memory loss and confusion are possible symptoms. Memory problems can affect day-to-day functioning, making it challenging to do regular chores. Although there is presently no cure for many underlying causes, early identification, cognitive therapy, medications, and lifestyle modifications may help control symptoms. Moreover, its rising prevalence is anticipated to positively impact the landscape of memory disorders emerging drugs.
Report Coverage
The Memory Disorders Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into memory disorders therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for memory disorders. The memory disorders report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The memory disorders pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with memory disorders treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to memory disorders.
Memory Disorders Drug Pipeline Outlook
Disruptions in the brain areas that are in charge of memory, particularly the hippocampus and associated neural circuits, are frequently a part of the pathophysiology of memory disorders. For instance, the buildup of tau tangles and amyloid plaques in Alzheimer's disease impairs synapse function and neural communication. Acetylcholine and other neurotransmitters are reduced as a result of neurodegeneration, which affects cognitive functions. Damage to brain cells and vascular structures may impair the brain's capacity to store and recover memories in various situations, such as stroke or traumatic brain injury, which can impact learning and memory.
Small molecules are most frequently used to treat memory impairments, especially Alzheimer's disease. These include NMDA receptor antagonists like memantine and cholinesterase inhibitors like donepezil. By improving neurotransmission and delaying the course of the disease, these medications aid in symptom management. Small molecules continue to be the standard because of their blood-brain barrier-crossing capabilities, ease of administration, and long-standing clinical use in treating cognitive decline and memory impairment, even if monoclonal antibodies, such as those that target amyloid plaques, are developing therapeutics. Further, the rising focus on the development of memory disorders emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Memory Disorders Epidemiology
Millions of people suffer from memory impairments, such as dementia and Alzheimer's disease, whose prevalence increases dramatically with age. Nearly 50 million people worldwide suffered from memory impairments in 2015 and by 2035, this number is expected to quadruple. Dementia affects more than 55 million people today, and over 10 million new cases are diagnosed each year. By 2050, there will be 13 million Alzheimer's patients in the United States, up from the current 6.9 million. Age is a significant risk factor. Dementia affects about 25% of those aged between 80–84 and 30%–50% of people over 85, while Finland reports a 33% prevalence in this age group. There are differences in diagnostic rates, with non-Hispanic White people and those with college degrees having greater rates.
Memory Disorders – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of memory disorders drug candidates based on several segmentations including:
By Phase
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook